EIRGENIX INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 84.5 TWD | -2.09% |
|
+5.62% | -15.92% |
| 05-15 | EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 03-22 | EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
ETFs positioned on EirGenix Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 114 M€ | +5.60% | - | |
| 0.00% | 32 M€ | +4.82% | - |
EirGenix Inc is a Taiwan-based company primarily engaged in the development of antibody drugs and the manufacture of biopharmaceuticals. Its main businesses include the provision of Contract Development & Manufacturing Organization (CDMO) services, the construction of cell strain, the manufacture of clinical trial medicine, analytical science and protein identification, and PIC/S manufacturing plant to provide clinical trial drug production.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
84.5
TWD
Average target price
112.5
TWD
Spread / Average Target
+33.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.92% | 802M | |
| +0.46% | 91.38B | |
| -2.37% | 38.68B | |
| +71.99% | 27.84B | |
| -12.31% | 16.05B | |
| -4.54% | 13.48B | |
| -10.83% | 11.73B | |
| +180.20% | 10.74B | |
| -48.60% | 10.39B | |
| +1.95% | 8.94B |
- Stock Market
- Equities
- 6589 Stock
- Funds and ETFs EirGenix Inc.
